Applied Genetic Technologies logo

AGTC - Applied Genetic Technologies News Story

$3.84 -0.0  -1.0%

Last Trade - 17/05/21

Small Cap
Market Cap £115.9m
Enterprise Value £85.3m
Revenue £n/a
Position in Universe 4697th / 6846

AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials

Thu 25th March, 2021 11:00am
For best results when printing this announcement, please click on link below:

-AGTC’s deep commitment to the patient voice drives solutions to support
patient access to information and to improve the experience of patients
participating in clinical trials-

GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) --
Applied Genetics Technologies Corporation (Nasdaq: AGTC), a biotechnology
company conducting human clinical trials of adeno-associated virus (AAV)-based
gene therapies for the treatment of rare diseases, which include X-linked
retinitis pigmentosa (XLRP) and achromatopsia (ACHM), announces two important
initiatives to help patients with potential interest in its XLRP clinical
trials. The first is an enhanced website to improve the experience for
patients with low vision, and the second is a dedicated patient information
call center to provide support to patients with potential interest in AGTC’s
clinical trials for XLRP.

AGTC has long recognized the importance of patients’ views in understanding
and serving their needs and launched its Patient Advisory Council (PAC)
in August 2020 to incorporate patient and caregiver voices into its culture
and clinical and pre-clinical programs. Along with guidance from the global
advocacy community on low vision, which included the Foundation Fighting
Blindness, Fighting Blindness Canada and Retina International, AGTC has
improved its website to make it more accessible and welcoming. These
enhancements to the website (, which are intended to make
information easier to find for patients with low vision, include different
font sizes and color options to make the pages easier to read and an option
for the page to be read aloud. Because AGTC recognizes the increasing use of
mobile devices by patients, these enhanced features are designed for mobile

In addition to upgrading the AGTC website, AGTC also has developed a website
that is dedicated to XLRP information and can be accessed at

“For those with low vision there is often a feeling of the loss of
independence and control, yet they are committed to learning more about their
condition, seeking treatment and researching relevant clinical trials,” said
Benjamin Yerxa, PhD, Chief Executive Officer of Foundation Fighting Blindness.
“I am grateful that AGTC sought feedback not only from their Patient
Advisory Council, but also from international advocates, and then incorporated
that feedback into their website redesign. This is a major step to help
patients gain control of their treatment research.”

To assist those who want to learn more about AGTC’s XLRP clinical trials,
AGTC partnered with Serva Health, a nurse-staffed patient engagement center,
to assist them in navigating the clinical trial experience. This partnership
provides access to nurses who can answer questions to help potential
participants better understand the XLRP clinical trials. If a potential
patient is interested and qualified for AGTC’s trial, the call center will
provide guidance and logistical support to navigate the process.

“Building relationships with the global advocacy community and listening to
families and caregivers provides us with valuable insights into patients’
unique unmet medical needs and the challenges they face when interested in
learning more about their indication and research into potential treatment
options,” said Sue Washer, President and CEO of AGTC. “This dialogue
equips us with the information we need to accomplish our goals of being
transparent in the clinical trial design process, conducting research,
providing education and support to patients, and delivering high-value
solutions throughout the patient journey.”

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and constructing all
critical gene therapy elements and bringing them together to develop
customized therapies that address real patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on
the Company’s industry leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates to address
substantial unmet clinical need in optogenetics, otology and CNS disorders. In
recent years AGTC has entered into strategic partnerships with companies
including Otonomy, a biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology, and Bionic Sight, an innovator in
the emerging field of optogenetics and retinal coding. 

David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485 or

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.